https://www.abtinnovations.ca/home daily 1.0 2021-08-09 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/0b89f8ed-465b-4127-a928-92bdd2b9bcc2/ABT_AntibiofilmPept_wide_V4_big.png Home https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/a3a2f427-ab0a-4615-b358-5868bf59593e/ABT_ImmunePeptide_Wide_V4_big.png Home https://www.abtinnovations.ca/contact-us daily 0.75 2026-02-23 https://www.abtinnovations.ca/partners daily 0.75 2026-02-23 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/b4f1514b-e434-41f9-9821-63592685cad6/bondent.png Partners https://www.abtinnovations.ca/management daily 0.75 2026-03-05 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/f0c2ecbc-afa6-4fc6-b06b-7b6ba8683f74/27.01.23_Aspen_4391.jpg Management https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/891c0d1c-c102-46d8-b0ac-cae0cb255725/27.01.23_Aspen_4531.jpg Management https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/7b102dda-c3f3-4fbc-ab98-a70c8e7132af/27.01.23_Aspen_4478.jpg Management https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/82d30296-dc17-4d0c-b711-d314c6743c9a/Derrold.jpg Management https://www.abtinnovations.ca/intellectual-property daily 0.75 2021-08-09 https://www.abtinnovations.ca/publications daily 0.75 2026-03-04 https://www.abtinnovations.ca/news daily 0.75 2026-02-23 https://www.abtinnovations.ca/technology daily 0.75 2021-08-04 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1628095562784-54911ARAFYDZNWYQOSGA/ABT_AntibiofilmPept_wide_V4_big.png Technology https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1628095581493-C9FAGQXJ53LZ7OHJ3V4X/ABT_ImmunePeptide_Wide_V4_big.png Technology https://www.abtinnovations.ca/treating-biofilm-infections-1 daily 0.75 2026-03-13 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1628095683563-WB1R3NEET8CYWAPZYICA/ABT_AntibiofilmPept_wide_V4.png Treating Biofilm Infections - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1627678029939-EV9M66WFLHKA7JBRNH68/fIG2V2.png Treating Biofilm Infections ABT peptides possess broad spectrum antibiofilm activity. They strongly inhibit biofilm formation and can eradicate and/or kill preformed biofilms. Fig.: Broad-Spectrum Anti-biofilm Peptide That Targets a Cellular Stress Response. PLoS Pathogens. doi: 10.1371/journal.ppat.1004152 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1627929896844-MKKS7HMA97BYG08AI8QE/FIG2v3.png Treating Biofilm Infections - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1627580184488-F1RRIPJ75HJXBYS30LEM/ABT%2BAntibiofilm%2BPeptides%2BImages%2B3.jpg Treating Biofilm Infections Activity of ABT Antibiofilm Peptides against oral plaque biofilms. Shown are confocal laser scanning microscopy images of live (green) and dead (red) stained oral plaque biofilms obtained from healthy volunteers and grown on hydroxyapatite discs. Compared to untreated samples, or treatment with 2% chlorhexidine (A), ABT peptide treatment strongly enhanced biofilm killing both on their own (B) and when used in combination with chlorhexidine (C). Fig.: Treatment of Oral Biofilms by a D-Enantiomeric Peptide. PLoS ONE. doi: 10.1371/journal.pone.0166997 https://www.abtinnovations.ca/immunomodulatory-agents daily 0.75 2026-03-13 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1628095662853-4DK4N49YHUVILHN9XPQ7/ABT_ImmunePeptide_Wide_V4+%281%29.png Immunomodulatory Agents - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1627580898857-R02OCXOYNV0CH353KMYC/Mouse+Model.png Immunomodulatory Agents ABT peptide dampened the inflammatory response in a sterile model of inflammation in mice. Inflammation in the mouse ears was induced by application of phorbol myristate acetate and treated topically with an anti-inflammatory ABT peptide, IDR-1002. In vivo imaging was performed 6 hours post treatment. To visualize reactive oxygen and reactive nitrogen species production the luminescent probe, L-012, was employed and mice were imaged using an IVIS Spectrum (A). To detect neutrophil recruitment, a neutrophil-specific probe, NIR Fluorescent Imaging Agent, was used and mice were again imaged using an IVIS Spectrum (B). In both cases, peptide treatment reduced the fluorescent signal arising from the inflammation specific chemical probes, reflecting their strong anti-inflammatory activity. Fig.: Mechanisms of the Innate Defense Regulator Peptide-1002 Anti-Inflammatory Activity in a Sterile Inflammation Mouse Model. J Immunol. doi: 10.4049/jimmunol.1700985. https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1627581597193-49TSS00NCW84229Q0LKS/Immuno+Pep+3.png Immunomodulatory Agents ABT Immunomodualtory Peptide, IDR-1018, enhances wound healing in an infected porcine model of skin wound infection. Fig.: Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS ONE. doi: 10.1371/journal.pone.0039373. https://www.abtinnovations.ca/vaccine-adjuvants daily 0.75 2021-07-08 https://www.abtinnovations.ca/about-abt daily 0.75 2021-08-09 https://www.abtinnovations.ca/dr-evan-haney daily 0.75 2021-07-30 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1625259945756-GIMTZE8RR1B21MYSBRJA/UBC_T2C5052.jpg Dr. Evan Haney - Dr. Evan Haney Chief Scientific Officer Dr. Haney is an experienced scientist and research coordinator who has managed a team of up to 20 individuals over the past 10 years. He is an inventor on the peptide patents that are core to ABT’s therapeutic technology and has in-depth experience with the various endeavors relevant to clinical research. He has published over 40 papers in scientific journals, including two major reviews in Nature journals related to peptide optimization and their development as therapeutics. Dr. Haney holds a Ph.D. in Biochemistry from the University of Calgary. https://www.abtinnovations.ca/about-1-1 daily 0.75 2021-09-07 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1625260077211-0YT7MW5C6H7EZR1H8H2Z/UBC_T2C5431.jpg Dr. Bob Hancock - Dr. Robert Hancock Chairman Dr. Hancock, OC, OBC, FRSC, is a leading microbiologist in the world and has researched and taught at the University of British Columbia for more than 40 years. The fundamental interest of Hancock and his laboratory is in designing new strategies to treat infections and inflammation in the light of increasing antibiotic resistance. He has founded four companies including Sepset and ABT and holds 67 patents. One of the most highly cited researchers in the world, Dr. Hancock has received the ICAAC antimicrobial research award (world's leading award for antimicrobial research, Canada's three leading Health Research Awards and the Prix Galien award for pharmaceutical research. Hancock Lab https://www.abtinnovations.ca/rudy-a-mazzocchi daily 0.75 2021-07-30 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1626112156443-AZFI8FNLI38528ITZB44/20190418_080151.jpg Rudy A. Mazzocchi - Rudy A. Mazzocchi Chief Executive Officer Over 30 years of Senior Executive Management, Technology and Intellectual Property Development, and Financing Experience (institutional, venture, private and public) in the Med-tech, Biotech, and Biopharma industries. As a founder of over a dozen Healthcare companies, Rudy has developed and commercialized multiple technologies ranging from diagnostics to implantable medical devices, requiring demanding clinical validation and regulatory reviews, including FDA Clearance, CE Mark, and International Regulatory Approvals. https://www.abtinnovations.ca/jennifer-gretchen daily 0.75 2021-07-12 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1626111948052-607XOO749QGF0B1OQ7HY/Jen+Gretchen.jpg Jennifer Gretchen - Jennifer Gretchen Chief Financial officer Jen is an experienced finance and accounting professional. She obtained her CA designation in 2014 from the Canadian Institute of Chartered Accountants while articling with KPMG Vancouver in the technology and telecommunications sector. She has managerial experience in financial planning, analysis and reporting. She has spent her career working with progressive tech companies including Qualcomm Incorporated and has assisted multiple companies through IPO and M&A transactions. https://www.abtinnovations.ca/mike-graw daily 0.75 2021-07-12 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/1626112017500-LXXH1CEY9C9WZRLX73D8/Mike_Headshot+mm.jpg Mike Graw - Mike Graw Chairman Bio coming soon! https://www.abtinnovations.ca/careers daily 0.75 2022-10-11 https://www.abtinnovations.ca/tim-murphy daily 0.75 2023-04-04 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/f0c2ecbc-afa6-4fc6-b06b-7b6ba8683f74/27.01.23_Aspen_4391.jpg Tim Murphy - Tim Murphy Chief Operations Officer Tim is an experienced business executive and international lawyer. He sits on numerous company boards and is the Founding Partner of Murphy & Company LLP, a leading business law firm in Vancouver, Canada. Prior to founding Murphy & Company, he practised law with a prominent national law firm in Calgary, Alberta, gained international experience as an associate in the finance law group of a British “magic circle” law firm and served as in-house legal counsel for a multinational software company in Paris, France. Tim holds a bachelor of laws (LL.B) degree from the University of Saskatchewan, a master of laws (LL.M) degree from McGill University and is a member of the law societies of British Columbia and England & Wales. https://www.abtinnovations.ca/derrold-norgaard daily 0.75 2026-03-05 https://images.squarespace-cdn.com/content/v1/60106dca9aa2af644f7c6f6d/82d30296-dc17-4d0c-b711-d314c6743c9a/Derrold.jpg Derrold Norgaard - Derrold Norgaard Chief Financial Officer Derrold Norgaard is a Fellow of the Chartered Professional Accountants of British Columbia. He held the dual role of Tax Partner and Office Managing Partner at KPMG until 2008. Norgaard’s primary areas of practice include personal tax planning, international tax and corporate taxation. He has authored several articles on Canadian tax planning and has been an instructor in Canadian tax programs for many years. He is a frequent speaker to business groups throughout Canada and Asia.